Invivyd (IVVD) Gains from Investment Securities (2020 - 2025)
Invivyd (IVVD) reported Gains from Investment Securities of -$23000.0 for Q4 2025, up 99.67% on a YoY basis from -$11519.3 in Q4 2024, and down 105.75% quarter-over-quarter from $400000.0 in Q3 2025.
Invivyd (IVVD) Gains from Investment Securities (2020 - 2025) Analysis & Trends
Invivyd has reported Gains from Investment Securities for 6 years, with the latest figure at -$23000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 99.67% year-over-year to -$23000.0; the trailing twelve-month figure through Dec 2025 stood at -$6.7 million (changed 0.16% YoY), and the FY2025 full-year result was $2.1 million, down 85.99% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$23000.0, down from $400000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $17.5 million in Q3 2021, with the low at -$6.9 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $1.4 million across 5 years, with a median of $100000.0 in 2023.
- The largest YoY upside for Gains from Investment Securities was 5766.87% in 2024 against a maximum downside of 57208.33% in 2024.
- Invivyd's Gains from Investment Securities stood at -$6.0 million in 2021, then soared by 31.75% to -$4.1 million in 2022, then soared by 99.71% to -$12000.0 in 2023, then plunged by 57208.33% to -$6.9 million in 2024, then jumped by 99.67% to -$23000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$23000.0 (Q4 2025), $400000.0 (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,000.00 |
| Dec 31, 2025 | -23,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | -6.88 Mn |
| Dec 31, 2024 | -6.88 Mn |
| Sep 30, 2024 | 5.87 Mn |
| Sep 30, 2024 | 5.87 Mn |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |